DCC5559 |
Xstax-vhll |
Novel selective β-catenin degrader |
|
DCC5560 |
Xylariamide A |
Carbonic anhydrase inhibitor; Fungal metabolite |
|
DCC5561 |
Xylarianaphthol-1 |
Novel activator of p21 promoter in a p53-independent manner |
|
DCC5562 |
Y08624 |
Novel TRIM24/BRPF1 dual inhibitor with IC 50 values of 0.98 and 1.16 μM, respectively |
|
DCC5563 |
Y2 Antagonist 36 |
Novel non-peptidic highly potent, soluble and selective NPY Y2 antagonist |
|
DCC5564 |
Y2-antagonist-2 |
Novel, selective, soluble non-peptidic NPY Y2 receptor antagonist with enhanced CNS exposure |
|
DCC5565 |
Y-39983 Dihydrochloride |
Selective Rho-associated kinase (ROCK) inhibitor |
|
DCC5566 |
Yak037 |
Tamoxifen-analog that Suppresses Glial L-Glutamate Transport Activity without Interaction with Estrogen_receptor>Estrogen Receptors |
|
DCC5567 |
Ycw-e11 |
Novel Inhibitor of Antiapoptotic Bcl-2 Family Proteins |
|
DCC5568 |
Yh18968 |
Novel GPR119 Agonist, improving glucose tolerance and augmenting the glucose lowering effect as well as the plasma level of active GLP-1 in normal mice in combination treatment with a dipeptidyl peptidase 4 (DPP-4) inhibitor |
|
DCC5569 |
Yh-gka |
Novel glucokinase activator, significantlt decreasing in blood glucose levels with no adverse effects on serum lipids or body weight |
|
DCC5570 |
Yk-5-252 |
Novel dual action combretastatin A-4 (CA-4) prodrug, releasing CA-4 through a disulfide bond cleavage mechanism and containing a near-infrared (NIR) fluorophore |
|
DCC5571 |
Ykl-05-093 |
Novel salt inducible kinase (SIK) inhibitor, increasing bone formation and bone mass |
|
DCC5572 |
Ylt192 |
Novel, Orally Active Bioavailable Inhibitor of VEGFR2 Signaling with Potent Antiangiogenic Activity and Antitumor Efficacy |
|
DCC5573 |
Ylt205 |
Novel Inducer of Apoptosis in Human Colorectal Cells via Mitochondrial Apoptosis Pathway, Inhibiting Tumor Growth |
|
DCC5574 |
Ym-17690 |
Novel non-analogous leukotriene agonist |
|
DCC5575 |
ym-201627 |
Selective growth inhibitor of endothelial cells |
|
DCC5576 |
Ym-244769
Featured
|
YM-244769 is a potent, selective and orally active Na+/Ca2+ exchanger (NCX) inhibitor. YM-244769 preferentially inhibits NCX3 and suppresses the unidirectional outward NCX current (Ca2+ entry mode), with IC50s of 18 nM and 50 nM, respectively. YM-244769 efficiently protects against hypoxia/reoxygenation-induced SH-SY5Y neuronal cell damage. YM-244769 can also increase urine volume and urinary excretion of electrolytes in mice. |
|
DCC5577 |
ym-298198 Dihydrochloride |
Potent and selective mGLu1 antagonist |
|
DCC5578 |
Ym-90k |
Novel AMPA receptor antagonist |
|
DCC5579 |
Yml220 |
Potent and selective microbicidal agent against wild type (wt) HIV-1, NNRTI-, NRTI-, PRI-resistant mutants |
|
DCC5580 |
Ynt-1310 |
Water-soluble analog of YNT-707, acting as a potent orexin 1 receptor (OX1R) antagonist |
|
DCC5581 |
Ynt-707 |
Novel potent orexin 1 receptor (OX1R) antagonist |
|
DCC5582 |
Yoyo-1 |
DNA-intercalating dye as sensitive amyloid probe |
|
DCC5583 |
Ysy01a |
Novel Proteasome Inhibitor, Enhancing Cisplatin Cytotoxicity in Cisplatin-Resistant Human Ovarian Cancer Cells, inducing cell cycle arrest on G2 phase in MCF-7 cells via ERα and PI3K/Akt pathways |
|
DCC5584 |
Yt-146 |
Selective A 2A receptor agonist |
|
DCC5585 |
Yu2534342249 |
Novel γ-lactam pyrazolidinone, targeting penicillin-binding proteins (PBPs) and incorporating a siderophore moiety to facilitate uptake into the periplasm, being effective against multidrug-resistant gram-negative Bacilli |
|
DCC5586 |
Yw2065 |
Novel inhibitor of Wnt signaling by stabilizing Axin-1, a scaffolding protein that regulates proteasome degradation of β-catenin |
|
DCC5587 |
Yycg Inhibitor 16 |
Novel YycG inhibitor, inhibiting planktonic cells of E. faecalis, including the vancomycin- or linezolid-resistant strains |
|
DCC5588 |
Yycg Inhibitor 62 |
Novel YycG inhibitor, significantly inhibited biofilm formation in static and dynamic conditions |
|